GSK’s new chief executive announced plans to narrow the focus of the group’s drug research by ditching 30-plus projects to improve returns in its core pharma business.
Manufacturers and their communications agencies see great opportunities in a new draft guidance from FDA, but the fear of warning letters still shadows the industry.
Market pressures have continued to threaten pharmaceutical brand revenue while increasing costs. The convergence of these two forces has challenged pharmaceutical manufacturers to improve margin with new and ever-evolving strategies. Only a combination of sophisticated managed markets expertise and real-world analysis can empower brands to maximize profitability in today’s challenging climate.
R&D success and M&A activity loom as large swing factors for the bio sector in 2017 with the regulatory arena potentially at its most amenable for years.
The HBA’s 28th annual Woman of the Year luncheon was held on May 11th at the New York Hilton Midtown.
Lurking behind all the sound and fury in the political realm, 2017 is bringing new opportunities to marketers that have nothing at all to do with orange hair. A whole generation of technologies are growing to maturity together – predictive targeting, virtual reality, behavioral science, interactive video, big data, and more – all of which are transforming the ways in which brands can communicate with their audiences. But of course politics will matter too in this Year One of the Trump administration, as the continuing debate over drug pricing and the impact of the new president’s policies on the pharma industry remain very much up in the ai
Despite the general anxiety over the impact of President Trump’s policies, when it comes to pharmaceutical sales forces, little of what he does will actually affect pharma sales-force strategies. The trends that are continuing to play out are declining rep access, the size of pharma sales forces, and the struggle with the concept of key account management, as well as trying to figure out how reps should be compensated.
U.S. trends in aggregate spend, disclosure, and transparency: Writing the next chapter on transparency initiatives
QuintilesIMS’ annual survey of pharmaceutical and device manufacturers was initiated in 2009 – when only a handful of U.S. states required disclosure of certain healthcare practitioner payments. Since then, of course, state, federal and global requirements have continually evolved and expanded. Our latest survey findings, which reflect responses from 112 manufacturers, underscore that while the bar keeps getting higher, manufacturers’ confidence and sophistication are also on the rise.
“Failing to plan is planning to fail” states time management guru Alan Lakein. Nowhere does this axiom ring more true than in the tightly controlled world of Rx launches. Given the time and expense required to bring a prescription drug to market, coupled with its limited exclusive lifespan, we must maximize every moment from market conditioning to loss of exclusivity (LOE).
Takeda and BioSurfaces announced a deal to initiate a research program designed to develop innovative medical devices to treat patients with GI diseases.
Eli Lilly reported an increase of 8 percent in second-quarter 2017 revenue, but the real shake-up is what the company plans to do with its pipeline.
Eli Lilly and Nektar Therapeutics announced a strategic collaboration to co-develop NKTR-358, a novel immunological therapy discovered by Nektar.
Shares of Israel-based NeuroDerm Limited soared more than 16 percent in premarket trading after the company announced it was being snapped up by Tokyo-based Mitsubishi Tanabe Corporation.
Corning announced at President Trump’s “Made in America” event that the company planned to create 1,000 new high-tech jobs in the U.S.
July 21, 2017 By Alex Keown, BioSpace.com Breaking News Staff LONDON – After a period of uncertainty, AstraZeneca (AZN) Chief Executive Officer Pascal Soriot finally broke his silence to squelch rumors he was departing the company and urged his employees to remain focused on the company’s goals. In an internal memo sent earlier this week […]
July 21, 2017 By Alex Keown, BioSpace.com Breaking News Staff DUBLIN – Less than one month after Endo International (ENDP) agreed to pull its opioid pain medication, the reformulated Opana ER, from the market, the company announced it was shuttering a manufacturing facility in Alabama and terminating hundreds of employees. Endo said the move follows […]
French drugmaker Sanofi boosted its early-stage pipeline in immunology by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).
Novartis CEO Joe Jiminez spoke with investors and analysts regarding the company’s half-year financials.
July 18, 2017 By Mark Terry, BioSpace.com Breaking News Staff Chicago, Ill. – Takeda Pharmaceuticals (TKPYY) is shifting hundreds of executives from the Chicago area to relocate to Boston. It is also cutting hundreds of field sales positions throughout the U.S. In March, the company indicated it was making job cuts in the Cambridge, […]
UDG Healthcare plc announced the acquisition of Cambridge BioMarketing LLC, a U.S.-based healthcare communications business, for a total consideration of up to $35 million.
Valeant Pharmaceuticals is selling its Obagi Medical Products business to Haitong International Zhonghua Finance Acquisition Fund I for $190 million in cash.
Health insurer Anthem Inc. filed a lawsuit against Insys Therapeutics Inc., alleging the drugmaker fraudulently obtained reimbursements for its opioid painkiller Subsys.
From the leaders of marketing teams to medical affairs, pharma executives are increasingly required to do more with less. While this is true across industries, the U.S. biopharma industry is faced with unique headwinds.
Novo Nordisk and Glooko advance their digital health collaboration with launch of unique integrated app for improved diabetes management
Novo Nordisk and Glooko announced that the new Cornerstones4Care Powered by Glooko app (C4C app) is now available to help people more effectively manage their diabetes.
Eli Lilly entered into a settlement agreement with generic companies to resolve pending patent litigation regarding the Cialis (tadalafil) unit dose patent.
OncoMed announced GlaxoSmithKline was terminating its nearly 10-year-old R&D agreement. OncoMed’s shares fell about 2 percent on the news.
Nestle is investing 20 million euros in a joint venture with Enterome SA to develop microbiome-based diagnostics for inflammatory bowel and liver diseases.
Roche’s bid to take a chunk of the hemophilia drug market dominated by Shire took another blow with the Irish company winning a preliminary injunction.